Can-Fite BioPharma


About: Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).

Employees: 5

Funds holding %
of 6,656 funds
Analysts bullish %
News positive %
of 5 articles

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

200% more capital invested

Capital invested by funds: $179K [Q3] → $536K (+$357K) [Q4]

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

13% more funds holding

Funds holding: 8 [Q3] → 9 (+1) [Q4]

0.01% more ownership

Funds ownership: 0.01% [Q3] → 0.02% (+0.01%) [Q4]

Research analyst outlook

We haven’t received any recent analyst ratings for CANF.

Financial journalist opinion

Based on 5 articles about CANF published over the past 30 days